Standardized Protocol Alters Medication Use in Pediatric Cannabis Hyperemesis Syndrome

The Rising Clinical Burden of Adolescent Cannabis Hyperemesis Syndrome

Cannabis hyperemesis syndrome has emerged as a significant challenge in emergency medicine, characterized by cyclical episodes of intractable nausea and vomiting in chronic users that frequently resist conventional antiemetic therapy [1]. The condition often necessitates specialized interventions such as topical capsaicin or antipsychotics, yet these treatments require careful navigation of risks including electrolyte imbalances and QTc prolongation, a delay in cardiac repolarization that can predispose patients to dangerous arrhythmias [2, 3]. Because these patients often present with high healthcare utilization and frequent return visits, establishing consistent diagnostic and treatment frameworks is essential for optimizing acute care [4]. Current guidelines emphasize the need for nonjudgmental, evidence-based protocols to abort acute episodes and reduce the burden on emergency resources [3]. A recent study evaluated how the formal implementation of a standardized management algorithm influenced prescribing habits and patient outcomes in a pediatric emergency department.

Retrospective Analysis of a Standardized Management Pathway

Standardizing the acute management of cannabis hyperemesis syndrome represents a critical step toward reducing practice variability in high-acuity settings. Researchers conducted a retrospective analysis of adolescent encounters at an academic pediatric emergency department to evaluate clinical outcomes following the implementation of a standardized management algorithm. The study period spanned four years, from July 2020 to July 2024, capturing data both before and after the clinical pathway was introduced. Investigators initially screened 533 encounters to identify patients presenting with symptoms consistent with the syndrome. From this initial pool, 128 encounters met the specific inclusion criteria, representing a cohort of 44 unique patients. This retrospective design allowed the team to compare medication administration patterns, hospital disposition, and resource utilization across two distinct time periods, providing a clear view of how institutional protocols translate into bedside practice.

Statistical Modeling of Clinical and Operational Variables

Rigorous statistical controls were employed to isolate the effect of the management algorithm from the inherent noise of emergency department operations. The researchers utilized mixed-effects models (a statistical approach that accounts for both fixed factors, such as the protocol implementation, and random factors, such as individual patient variability) to examine the association between the study period and clinical outcomes. These models were adjusted for several confounding variables, including patient age, sex, and the emergency severity index level (a five-level triage tool used to categorize patient acuity based on the urgency of their clinical needs). For the analysis of emergency department length of stay, the model also accounted for total daily arrivals to control for the effects of department crowding on patient throughput. These methods allowed the investigators to determine if the observed shifts in clinical practice, such as the increase in capsaicin administration from 2.7% to 22.2% (P < 0.001) and metoclopramide use from 6.8% to 42.6% (P < 0.001), were statistically significant.

Shifts in Pharmacological Intervention Patterns

The implementation of the standardized management algorithm led to a marked shift in the selection of antiemetic and adjunctive therapies, favoring agents with specific mechanisms of action for this syndrome. Clinicians significantly increased their utilization of capsaicin, a topical agent that targets transient receptor potential vanilloid 1 receptors (sensory receptors involved in pain and heat sensation) to alleviate symptoms, with administration rates rising from 2.7% to 22.2% (P < 0.001). Similarly, the use of metoclopramide, a dopamine-receptor antagonist frequently employed for its prokinetic and antiemetic properties, saw a substantial increase from 6.8% to 42.6% (P < 0.001). While the frequency of haloperidol administration did not change significantly (20.3% vs. 9.3%, P = 0.138), the mean dose of haloperidol decreased significantly from 2.7 mg to 1.0 mg (P = 0.014). This reduction in dosage suggests that the protocol encouraged more conservative use of this antipsychotic, potentially minimizing the risk of dose-dependent adverse effects like extrapyramidal symptoms or cardiac conduction delays in the adolescent population.

Impact on Hospital Admission and Emergency Department Throughput

Despite the significant shifts in pharmacological management, the implementation of the standardized clinical pathway did not result in a statistically significant reduction in hospital resource utilization. The researchers found that the adjusted odds of hospital admission did not significantly differ after implementation (adjusted OR: 0.57, 95% CI: 0.17, 1.86). This suggests that while the protocol successfully standardized the bedside approach to symptom relief, the underlying clinical severity or the threshold for inpatient care remained consistent. Operational efficiency within the emergency department also remained stable, as the emergency department length of stay did not significantly differ (adjusted beta: -0.01, 95% CI: -0.21, 0.20). Ultimately, the algorithm implementation was associated with increased capsaicin and metoclopramide use but no change in admission rates or length of stay, highlighting that the primary impact of the pathway was the modification of provider prescribing patterns rather than a shift in broader disposition or throughput metrics.

Clinical Implications and Future Research Directions

For the practicing clinician, these findings underscore the difficulty of altering the clinical trajectory of cannabis hyperemesis syndrome through acute pharmacological intervention alone. This study, which evaluated 128 encounters involving 44 unique patients, demonstrates that while a standardized clinical pathway can successfully modify provider behavior, it may not immediately impact systemic metrics. The stability of hospital resource utilization, including the adjusted odds of admission and the adjusted length of stay, indicates that the physiological resolution of a hyperemetic episode may follow a timeline independent of the specific medications utilized in this protocol. Ultimately, the authors concluded that prospective studies are needed to assess optimal management in children to better understand the efficacy of dopamine antagonists and topical irritants. Until such trials are conducted, clinicians should view standardized pathways as tools for reducing practice variability while remaining cognizant of the need for individualized patient assessment in the emergency setting.

References

1. Smith SA, Safwat MA, Piper BJ, Addison MA. Unraveling the Enigma of Cannabinoid Hyperemesis Syndrome: A Narrative Review of Diagnosis and Management. Cureus. 2025. doi:10.7759/cureus.90961

2. Merino S, Tordera L, Jun A, Yang S. Mitigating the Risk of QTc Prolongation When Using Haloperidol for Acute Treatment of Cannabinoid Hyperemesis Syndrome in Adolescents and Young Adults. Journal of Clinical Medicine. 2024. doi:10.3390/jcm14010163

3. Levinthal DJ, Killian B, Issenman RM. Acute care of cyclic vomiting syndrome and cannabinoid hyperemesis syndrome in the home and emergency department. Neurogastroenterology & Motility. 2024. doi:10.1111/nmo.14901

4. Mohammad R, Exadaktylos AK, Santa VD, Heymann E. Cannabinoid hyperemesis syndrome and cannabis withdrawal syndrome: a review of the management of cannabis-related syndrome in the emergency department. International Journal of Emergency Medicine. 2022. doi:10.1186/s12245-022-00446-0